Obsessive-compulsive disorder, frontostriatal system and effect upon the serotonergic system;Zwangsstorung, frontostriatales system und beeinflussung des serotonergen systems

Zeitschrift fur Kinder- und Jugendpsychiatrie und Psychotherapie

Volumn 28, Issue 1, 2000, Pages 35-44

  Baving, L ^a   Schmidt, M H ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Basal ganglia; Frontal brain; Neuroimaging; Obsessive compulsive disorder; Serotonin reuptake inhibitors; Sulpiride

Indexed keywords

CLOMIPRAMINE; FLUVOXAMINE; SULPIRIDE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; BASAL GANGLION; CHILD PSYCHIATRY; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DISEASE ASSOCIATION; DRUG EFFICACY; FATIGUE; FEMALE; HEART DISEASE; HUMAN; LENGTH OF STAY; MALE; OBSESSION; PATHOPHYSIOLOGY; SEROTONINERGIC SYSTEM; TREATMENT OUTCOME; WEIGHT GAIN; ADOLESCENT; BEHAVIOR THERAPY; CHILD; COMPARATIVE STUDY; EPIDEMIOLOGY; METABOLISM; MULTIMODALITY CANCER THERAPY; OBSESSIVE COMPULSIVE DISORDER; PREFRONTAL CORTEX; RETROSPECTIVE STUDY;

ADOLESCENT; BEHAVIOR THERAPY; CHILD; CLOMIPRAMINE; COMBINED MODALITY THERAPY; FEMALE; FLUVOXAMINE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; PREFRONTAL CORTEX; RETROSPECTIVE STUDIES; SAMPLING STUDIES; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SULPIRIDE; TREATMENT OUTCOME;

EID: 0033625010     PISSN: 03016811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. Abramowitz, J.S.: Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. Journal of Consulting and Clinical Psychology 65, 44-52, 1997.
2. Baumgarten, H.G.; Grozdanovic, Z.: Role of serotonin in obsessive-compulsive disorder. British Journal of Psychiatry 173 (suppl. 35), 13-20, 1998.
3. Baxter, L.R.; Phelps, M.E.; Mazziotta, J.C.; Guze, B.H.; Schwartz, J.M.; Selin, C.E.: Local cerebral glucose metabolic rates in obsessive-compulsive disorder. A comparison with rates in unipolar depression and in normal controls. Archives of General Psychiatry 44, 211-218, 1987.
4. Baxter, L.R.; Schwartz, J.M.; Mazziotta, J.C.; Phelps, M.E.; Pahl, J.J.; Guze, B.H.; Fairbanks, L.: Cerebral glucose metabolic rates in nondepressed patients with obsessive-compulsive disorder. American Journal of Psychiatry 145, 1560-1563, 1988.
5. Baxter, L.R.; Schwartz, J.M.; Bergman, K.S.; Szuba, M.P.; Guze, B.H.; Mazziotta, J.C.; Alazraki, A.; Selin, C.E.; Ferng, H.K.; Munford, P.; Phelps, M.E.: Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder. Archives of General Psychiatry 49, 681-689, 1992.
6. Benkelfat, C.; Nordahl, T.E.; Semple, W.E.; King, A.C.; Murphy, D.L.; Cohen, R.M.: Local cerebral glucose metabolic rates in obsessive-compulsive disorder. Archives of General Psychiatry 47, 840-848, 1990.
7. Bergqvist, P.B.F.; Bouchard, C.; Blier, P.: Effect of long-term administration of antidepressant treatments on serotonin release in brain regions involved in obsessive-compulsive disorder. Biological Psychiatry 45, 164-174, 1999.
8. Blier, P.; de Montigny, C.: Possible serotonergic mechanisms underlying the antidepressant and anti-obsessive-compulsive disorder responses. Biological Psychiatry 44, 313-323, 1998.
9. Caley, C.F.; Weber, S.S.: Sulpiride: an antipsychotic with selective dopaminergic antagonist properties. Annals of Pharmacotherapy 29, 152-160, 1995.
10. Delgado, P.L.; Moreno, F.A.: Different roles for serotonin in anti-obsessional drug action and the pathophysiology of obsessive-compulsive disorder. British Journal of Psychiatry 173 (suppl. 35), 21-25, 1998.
11. DeVeaugh-Geiss, J.; Moroz, G.; Biederman, J.; Cantwell, D.; Fontaine, R.; Greist, J.H.; Reichler, R.; Katz, R.; Landau, Ph.: Clomipramine hydrochloride in childhood and adolescent obsessive-compulsive disorder - a multicenter trial. Journal of the American Academy of Child and Adolescent Psychiatry 31, 45-49, 1992.
12. 99mTc-exametazime shown by single photon emission computerized tomography in obsessive-compulsive disorder compared with major depression and normal controls. Acta Psychiatrica Scandinavica 90, 298-303, 1994.
13. El Mansari, M.; Bouchard, C.; Blier, P.: Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors. Neuropsychopharmacology 13, 117-127, 1995.
14. Fineberg, N.A.; Roberts, A.; Montgomery, S.A.; Cowen, P.J.: Brain 5-HT function in obsessive-compulsive disorder. British Journal of Psychiatry 171, 280-282, 1997.
15. Fitzgerald, K.D.; Stewart, C.M.; Tawile, V.; Rosenberg, D.R.: Risperidone augmentation of serotonin reuptake inhibitor treatment of pediatric obsessive compulsive disorder. Journal of Child and Adolescent Psychopharmacology 9, 115-123, 1999.
16. Flament, M.F.; Bisserbe, J.C.: Pharmacologic treatment of obsessive-compulsive disorder: Comparative studies. Journal of Clinical Psychiatry 58 (suppl. 12), 18-22, 1997.
17. Flament, M.F.; Rapoport, J.L.; Berg, C.J.; Sceery, W.; Kilts, C.; Mellström, B.; Linnoila, M.: Clomipramine treatment of childhood obsessive-compulsive disorder. Archives of General Psychiatry 42, 977-983, 1985.
18. Freeman, C.P.; Trimble, M.R.; Deakin, J.F.; Stokes, T.M.; Ashford, J.J.: Fluvoxamine versus clomipramine in the treatment of obsessive-compulsive disorder: a multicenter, randomized, double-blind, parallel group comparison. Journal of Clinical Psychiatry 55, 301-305, 1994.
19. Garber, H.J.; Ananth, J.V.; Chiu, L.C.; Griswold, V.J.; Oldendorf, W.H.: Nuclear magnetic resonance study of obsessive-compulsive disorder. American Journal of Psychiatry 146, 1001-1005, 1989.
20. Goodman, W.K.; Ward, H.; Kablinger, A.; Murphy, T.: Fluvoxamine in the treatment of obsessive-compulsive disorder and related conditions. Journal of Clinical Psychiatry 58 (suppl. 5), 32-49, 1997.
21. Grachev, I.D.; Breiter, H.C.; Rauch, S.L.; Savage, C.R.; Baer, L.; Shera, D.M.; Kennedy, D.N.; Makris, N.; Caviness, V.S.; Jenike, M.A.: Structural abnormalities of frontal neocortex in obsessive-compulsive disorder. Archives of General Psychiatry 55, 181-182, 1998.
22. Greist, J.H.: Behavior therapy for obsessive compulsive disorder. Journal of Clinical Psychiatry 55 (10 suppl.), 60-68, 1994.
23. Greist, J.H.; Jefferson, J.W.: Pharmacotherapy for obsessive-compulsive disorder. British Journal of Psychiatry 173 (suppl. 35), 64-70, 1998.
24. Greist, J.H.; Jefferson, J.W.; Kobak, K.A.; Katzelnick, D.J.; Serlin, R.C.: Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Archives of General Psychiatry 52, 53-60, 1995.
25. Hoehn-Saric, R.; Pearlson, G.D.; Harris, G.J.; Machlin, S.R.; Camargo, E.E.: Effects of fluoxetine on regional cerebral blood flow in obsessive-compulsive patients. American Journal of Psychiatry 148, 1243-1245, 1991.
26. Hollander, E.; Wong, C.M.: The relationship between executive function impairment and serotonergic sensitivity in obsessive-compulsive disorder. Neuropsychiatry, neuropsychology, and behavioral neurology 9, 220-233, 1996.
27. Horn, W.: Prüfsystem für Schul-und Bildungsberatung. Hogrefe, Göttingen, 1969.
28. King, R.A.; Leonard, H.; March, J.: Summary of the practice parameters for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 37, 1110-1116, 1998.
29. Koponen, H.; Leopola, U.; Leinonen, E.; Jokinen, R.; Penttinen, J.; Turtonen, J.: Citalopram in the treatment of obsessive-compulsive disorder an open pilot study. Acta Psychiatrica Scandinavica 96, 343-346, 1997.
30. Koran, L.M.; McElroy, S.L.; Davidson, J.R.; Rasmussen, S.A.; Hollander, E.; Jenike, M.A.: Fluvoxamine versus clomipramine in obsessive-compulsive disorder: a double-blind comparison. Journal of Clinical Psychopharmacology 16, 121-129, 1996.
31. Larson, C.L.; Davidson, R.J.; Abercrombie, H.C.; Ward, R.T.; Schaefer, S.M.; Jackson, D.C.; Holden, J.E.; Perlman, S.B.: Relations between PET-derived measures of thalamic glucose metabolism and EEG alpha power. Psychophysiology 35, 162-169, 1998.
32. Leonard, H.L.; Swedo, S.E.; Rapoport, J.L.; Koby, E.V.; Lenane, M.C.; Hamburger, S.D.: Treatment of obsessive-compulsive disorder with clomipramine and desipramine in children and adolescents. Archives of General Psychiatry 46, 1088-1092, 1989.
33. Leonard, H.L.; Swedo, S.E.; Lenane, M.C.; Rettew, D.C.; Cheslow, D.L.; Hamburger, S.D.; Rapoport, J.L.: Adouble-blind substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Archives of General Psychiatry 48, 922-927, 1991.
34. Lucey, J.V.; Costa, D.C.; Blanes, T.; Busatto, G.F.; Pilowsky, L.S.; Takei, N.; Marks, I.M.; Ell, P.J.; Kerwin, R.W.; Regional cerebral blood flow in obsessive-compulsive disordered patients at rest. British Journal of Psychiatry 167, 629-634, 1995.
35. Lucey, J.V.; Costa, D.C.; Adshead, G.; Deahl, M.; Busatto, G.; Gacinovic, S.; Travis, M.; Pilowsky, L.; Ell, P.J.; Marks, I.M.; Kerwin, R.W.: Brain blood flow in anxiety disorders. British Journal of Psychiatry 171, 346-350, 1997.
36. Luxenberg, J.S.; Swedo, S.E.; Flament, M.F.; Firedland, R.P.; Rapoport, J.; Rapoport, S.I.: Neuroanatomical abnormalities in obsessive-compulsive disorder detected with quantitative x-ray computed tomography. American Journal of Psychiatry 145, 1089-1093, 1988.
37. Machlin, S.R.; Harris, G.J.; Pearlson, G.D.; Hoehn-Saric, R.; Peffery, P.; Camargo, E.E.: Elevated medial-frontal cerebral blood flow in obsessive-compulsive patients: A SPECT study. American Journal of Psychiatry 48, 1240-1242, 1991.
38. Martinot, J.L.; Allilaire, J.F.; Mazoyer, B.M.: Obsessive-compulsive disorder: a clinical, neuropsychological and positron emission tomography study. Acta Psychiatrica Scandinavica 82, 233-242, 1990.
39. Monteleone, P.; Catapano, F.; Di Martino, S.; Ferraro, C.; Maj, M.: Prolactin response to d-fenfluramine in obsessive-compulsive patients, and outcome of fluvoxamine treatment. British Journal of Psychiatry 170, 554-557, 1997.
40. Nakazato, T.; Horikawa, H.P.; Akiyama, A.: The dopamine D2 receptor antagonist sulpiride causes long-lasting serotonin release. European Journal of Pharmacology 363, 29-34, 1998.
41. Neudörfl, A.; Herpertz-Dahlmann, B.: Der Verlauf von Zwangserkrankungen im Kindes-und Jugendalter - Eine Literaturübersicht. Zeitschrift für Kinder-und Jugendpsychiatrie und Psychotherapie 24, 105-116, 1996.
42. 18F]FDG PET study in obsessive-compulsive disorder. A clinical/ metabolic correlation study after treatment. British Journal of Psychiatry 166, 244-250, 1995.
43. Piccinelli, M.; Pini, S.; Bellantuono, C.; Wilkinson, G.: Efficacy of drug treatment in OCD: a meta-analytic review. British Journal of Psychiatry 166, 424-443, 1995.
44. Pigott, T.A.; Pato, M.T.; Bernstein, S.E.; Grover, G.N.; Hill, J.L.; Tolliver, T.J.; Murphy, D.L.: Controlled comparisons of clomipramine and fluoxetine in the treatment of obsessive-compulsive disorder: behavioral and biological results. Archives of General Psychiatry 47, 926-932, 1990.
45. Pigott, T.A.; Seay, S.M: A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. Journal of Clinical Psychiatry 60, 101-106, 1999.
46. Rapoport, J.; Elkins, R.; Mikkelsen, E.: Clinical controlled trial of clomipramine in adolescents with obsessive-compulsive disorder. Psychopharmacological Bulletin 16, 61-65, 1980.
47. Riddle, M.A.; Scahill, L.; King, R.A.; Hardin, M.T.; Anderson, G.M.; Ort, S.I.; Smith, J.C.; Leckman, J.F.; Cohen, D.J.: Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. Journal of the American Academy of Child and Adolescent Psychiatry 29, 766-772, 1992.
48. Riddle, M.: Obsessive-compulsive disorder in children and adolescents. British Journal of Psychiatry 173 (suppl. 35), 91-96, 1998.
49. Robinson, D.; Houwei, W.; Munne, R.A.; Ashtari, M.; Alvir, J.M.J.; Lerner, G.; Koreen, A.; Cole, K.; Bogerts, B.: Reduced caudate nucleus volume in obsessive-compulsive disorder. Archives of General Psychiatry 52, 393-398, 1995.
50. Rosenberg, D.R.; Keshavan, M.S.: Toward a neurodevelopmental model of obsessive-compulsive disorder. Biological Psychiatry 43, 623-640, 1998.
51. Rosenberg, D.R.; Keshavan, M.S.; O'Hearn, K.M.; Dick, E.L.; Bagwell, W.W.; Seymour, A.B.; Montrose, D.M.; Pierri, J.N.; Birmaher, B.: Frontostriatal measurement in treatment naive children with obsessive-compulsive disorder. Archives of General Psychiatry 54, 824-829, 1997.
52. Rothenberger, A.: Psychopharmacological treatment of self-injurious behavior in individuals with autism. Acta Paedopsychiatrica 56, 99-104, 1993.
53. Rubin, R.T.; Villanueva-Meyer, J.; Ananth, J.; Trajmar, P.G.; Mena, I.: Regional xenon 133 cerebral blood flow and cerebral technetium 99m HMPAO uptake in unmedicated patients with obsessive-compulsive disorder and matched normal control subjects. Archives of General Psychiatry 49, 695-802, 1992.
54. 99mTc-HMPAO uptake in patients with obsessive-compulsive disorder before and during treatment. Biological Psychiatry 38, 429-437, 1995.
55. Saxena, S.; Brody, A.L.; Schwartz, J.M.; Baxter, L.R.: Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder. British Journal of Psychiatry 173 (suppl. 35), 26-37, 1998.
56. Schütze, G.; Aldenhoff-Zöllner, A.; Arndt, R.; Haase, Ch.; Hinrichs, G.; Hobrücker, B.; Kühl, R.: Leitlinie Zwangsstörungen der Deutschen Gesellschaft für Kinder-und Jugendpsychiatrie und -psychotherapie, 1999 (http://www.uni-duesseldorf.de/WWW/AWMF/ll/kjpp-007.htm).
57. Steinhausen, H.C.: Eine Skala zur Beurteilung psychisch gestörter Kinder und Jugendlicher. Zeitschrift für Kinder-und Jugendpsychiatrie 13, 230-240, 1985.
58. Swedo, S.E.; Pietrini, P.; Leonard, H.L.; Schapiro, M.B.; Rettew, D.C.; Goldberger, E.L.; Rapoport, S.I.; Rapoport, J.L.; Grady, C.L.: Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Revisualization during pharmacotherapy. Archives of General Psychiatry 49, 690-694, 1992.
59. Swedo, S.E.; Schapiro, M:B.; Grady, C.L.; Cheslow, D.L.; Leonard, H.L.; Kumar, A.; Friedland, R.; Rapoport, S.I.; Rapoport, J.L.: Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder. Archives of General Psychiatry 46, 518-523, 1989.
60. Thoren, P.; Asberg, M.; Cronholm, B.; Jornested, L.; Traskman, L.: Clomipramine treatment of childhood obsessive-compulsive disorder. I: a controlled clinical trial. Archives of General Psychiatry 37, 1281-1285, 1980.
61. Tollefson, G.D.; Rampey, A.H.; Potvin, J.H.; Jenike, M.A.; Rush, A.J.; Dominguez, R.A.; Koran, L.M.; Shear, M.K.; Goodman, W.; Genduso, L.A.: A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Archives of General Psychiatry, 51, 559-567, 1994.
62. Zohar, R.; Judge, R., and the OCD Paroxetine Study Investigators: Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. British Journal of Psychiatry 169, 468-474, 1996.